Common Contracts
2 similar Investors’ Rights Agreement contracts by 10x Genomics, Inc., 10X Genomics, Inc.
10X GENOMICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • August 19th, 2019 • 10x Genomics, Inc. • Laboratory analytical instruments • California
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of October 18, 2018 by and among 10X Genomics, Inc., a Delaware corporation (the “Company”), Serge Saxonov, Benjamin Hindson and Kevin Ness (the “Founders”), the holders of Series A-1 Preferred Stock (the “Series A-1 Preferred”) and Series A-2 Preferred Stock (the “Series A-2 Preferred,” together with Series A-1 Preferred, the “Series A Stock”) of the Company, the holders of Series B Preferred Stock of the Company (the “Series B Stock”), the holders of Series C Preferred Stock of the Company (the “Series C Stock”), the holders of Series D Preferred Stock of the Company (the “Series D Stock”) and the purchasers of Series D-1 Preferred Stock of the Company (the “Series D-1 Stock”) listed on Schedule 1 (the “Investors”).
10X GENOMICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • June 20th, 2019 • 10X Genomics, Inc. • Laboratory analytical instruments • California
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of October 18, 2018 by and among 10X Genomics, Inc., a Delaware corporation (the “Company”), Serge Saxonov, Benjamin Hindson and Kevin Ness (the “Founders”), the holders of Series A-1 Preferred Stock (the “Series A-1 Preferred”) and Series A-2 Preferred Stock (the “Series A-2 Preferred,” together with Series A-1 Preferred, the “Series A Stock”) of the Company, the holders of Series B Preferred Stock of the Company (the “Series B Stock”), the holders of Series C Preferred Stock of the Company (the “Series C Stock”), the holders of Series D Preferred Stock of the Company (the “Series D Stock”) and the purchasers of Series D-1 Preferred Stock of the Company (the “Series D-1 Stock”) listed on Schedule 1 (the “Investors”).
